Neurocrine Biosciences Inc. (NBIX)
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know
Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why
Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $0.08 per share a year ago.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet
The consensus price target hints at a 38.8% upside potential for Neurocrine (NBIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock?
Investors need to pay close attention to NBIX stock based on the movements in the options market latel.
